2017-06-08 18:47:44 UTC

Advent of Biosimilar Products in US GI Practice

Duration

1.5

About

Learn about how biosimilars are used in the practice of gastroenterology in the US from this recording of the live session held during DDW 2017 in Chicago. Panelists and presentations include:

  • Introduction to Biosimilars (15 minutes)
    Gary R. Lichtenstein, MD, AGAF
  • The US Biosimilars Regulatory Pathway (20 minutes)
    M. Stacey Ricci, M.Eng., Sc.D.
  • Clinical Considerations In Use Of Biosimilars For Gastrointestinal Disorders (20 minutes)
    Brian G. Feagan, MD
  • Why Patients Should Know About Biosimilars (20 minutes)
    David T. Rubin, MD, AGAF
  • Panel Discussion (15 minutes)

This program is supported by independent educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Pfizer Inc.

This session is sponsored by the AGA Biosimilars Advisory Panel, Clinical Practice, Immunology, Microbiology & Inflammatory Bowel Diseases, and is a collaboration of the AGA Institute and the Crohn’s and Colitis Foundation.

CME Information

The American Gastroenterological Association (AGA) Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The AGA Institute designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.

CME expiration date:

Faculty Relationship and Financial Disclosures

Click here to view financial disclosures for presenters

Planning Committee

  • Gary R. Lichtenstein, MD, AGAF
  • Consultant: Abbvie, Alaven, Celgene/Santarus/Receptos, Ferring, Hospira, Janssen Orthobiotech, Luitpold/American Reagent, Pfizer, Prometheus, Salix Pharmaceuticals,
  • Shire, Takeda, UCB
  • Grant/Research Support: Celgene/Santarus/Receptos, Takeda
  • Honoraria: Clinical Advances in Gastroenterology, Ironwood, McMahon Publishing,
  • Merck, Romarck, Springer
  • Royalty: SLACK, Inc.

AGA Staff

Maura H. Davis
Disclosed no relevant financial relationships.

Monique S. Dyson, MS, CHES
Disclosed no relevant financial relationships.

Alison Kim, PhD
Disclosed no relevant financial relationships.

Crohn’s & Colitis Foundation Staff

Orna Ehrlich
Disclosed no relevant financial relationships.

Laura Wingate
Disclosed no relevant financial relationships.

Activity

 

Claim CME

 

Who Should Take this Course

This activity is intended for gastroenterologists, GI fellows, nurse practitioners, physician assistants and other health-care professionals who treat GI disorders.

More on IBD

Crohn's & Colitis Congress™ (A Partnership of the Crohn's & Colitis Foundation and American Gastroenterological Association)

Jan. 18, 2018

The Crohn's & Colitis Foundation and AGA are partnering on a new annual conference for health-care professionals and researchers. By joining the nation's leading IBD patient organization with the premier gastroenterological professional organization, this is the must-attend IBD conference, bringing state-of-the-art comprehensive care together with the latest research to advance prevention, treatment and cures for IBD patients.

Principles of Gastroenterology for the NP and PA

Aug. 11, 2017

Hear from the experts as they provide you with critical updates on treating and managing patients with a variety of GI disorders.

Watch IBD Program Highlights from DDW® 2017

June 26, 2017

The Immunology, Microbiology & Inflammatory Bowel Diseases Section highlights its favorite sessions from Chicago.